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Effect of Ascorbic Acid 2-Sulfate on the Faecal Excretion of Exogenous Cholesterol ih the Rat
1
By D. Hornig, F. Weber and O. Wiss
F. Hoffmann-La Roche & Co., Basle
(Eingegangen am 13. September/12. Dezember 1973)
The influence of intravenously administered ascorbic acid 2-sulfate, sodium ascorbate, or K2 SO4, given over a period of 5 days, on
the excretion behaviour of an exogenous dose of 14C-labeUed cholesterol was studied in normal female rats. No stimulatory effect of
ascorbic acid 2-sulfate or ascorbate was observed either on the faecal excretion of cholesterol or on that of cholesterol sulfate. On
the contrary, the excretion of radioactive material was significantly reduced after treatment with either ascorbic acid 2-sulfate or
with ascorbate when compared with the controls (treatment with buffer or K2SO4). The composition of the radioactive material in
the faeces was unaffected (cholesterol 90%, cholesterol sulfate 6%). Therefore, it is doubtful that the hypocholesterolemic effect of
ascorbic acid is due to the intermediate formation of ascorbic acid 2-sulfate.
Es wurde der Einfluß von Ascorbinsäure-2-sulfat, von Natriumascorbat und von Kaliumsulfat auf die Ausscheidung einer einzigen
exogenen Dosis von 14C-markiertem Cholesterin in weiblichen Ratten untersucht. Ascorbinsäure-2-sulfat, Natriumascorbat und
Kaliumsulfat wurden täglich über 5 Tage intravenös appliziert. Das markierte Cholesterin wurde 5 h nach der letzten Dosis dieser
Substanzen injiziert. Der Kot wurde 72 h gesammelt. Weder Ascorbinsäure-2-sulfat noch Ascorbat zeigten eine Stimulierung der Aus-
scheidung an Cholesterin und Cholesterinsulfat mit dem Kot. Im Vergleich zu den Kontrollen (Verabreichung von Puffer oder Kalium-
sulfat) ergab sich sogar eine signifikante Verminderung der Ausscheidung von markiertem Material. Die Zusammensetzung der De-
markierten Substanzen im Kot zeigte sich unbeeinflußt (Cholesterin 90%; Cholesterinsulfat, 6%). Die Ergebnisse verneinen die Hy-
pothese, daß die hypocholesterolämische Wirkung der Ascorbinsäure auf eine intermediäre Bildung von Ascorbinsäure-2-sulfat mit
anschließendem Sulfattransfer auf Cholesterin zurückzuführen sei.
Ascorbic acid 2-sulfate was shown to serve as a sulfating
agent in vitro at elevated temperature or under mild
oxidizing conditions (1, 2). The in vivo sulfation of
cholesterol by ascorbic acid 2-sulfate in the rat was
recently reported (3, 4). A single intracardial injection
of [35S]ascorbic acid 2-sulfate elevated the faecal ex-
cretion of cholesterol sulfate approximately fifty-fold.
The hypocholesterolemic effect of ascorbic acid, as re-
ported in man (5) as well as in laboratory animals (6, 7),
was postulated to be due to the intermediate synthesis
of ascorbic acid 2-sulfate with subsequent transfer of
the activated sulfate moiety onto cholesterol to form
cholesterol sulfate which is then flushed out of the
body (4). Ascorbic acid 2-sulfate was identified äs a
significant metabolite of ascorbic acid in animals and
man (8-10) and it has been suggested that it acts as a
long-term storage form in the ascorbic acid pool of
the body (11).
This report deals with the effect of ascorbic acid
2-sulfate, given over a period of 5 days by daily
intravenous injection, on the faecal excretion of
radioactivity after a single intravenous administration
of [4-14C]cholesterol in rats. The aim of this study
was to examine whether the administration of ascorbic
acid 2-sulfate enhances the faecal or urinary excretion
of radioactive material, especially of cholesterol sulfate,
and whether the accumulation of exogenous chole-
sterol by various tissues is decreased.
Materials and Methods
Chemicals: [4-14CJcholesterol (55.6 mCi/mmple), dissolved in
benzene, was purchased from The Radiochemical Centre,
Amersham. Ascorbic acid 2-sulfate (dipotassium salt), sodium
ascorbate and cholesterol sulfate (ammonium salt) were
supplied by Hoffmann-La Roche, Atlas G-1290 by Atlas"
Chemie (Essen, Germany). All other chemicals were of
reagent grade and from commercial sources. *
Animals: Female rats (strain Füllinsdorf Albino) were
maintained on a commercial diet (Nafag 199, by Nafag,
Gossau, Switzerland). They were divided into 3 groups
(SD given): controls (167.1 ± 9.4 g of weight) and two ex- "
perimental groups receiving 10 mg ascorbic acid 2-sulfate daily
(165.7 ± 16.2 g) or 20 mg ascorbic acid 2-sulfate daily
(165.2 ± 15.0 g). Ascorbic acid 2-sulfate was dissolved in
0.15 mol/1 sodium phosphate buffer, pH 7.4, to a final con-
centration of 10 or 20 mg/500 . The solutions were injected
daily for 5 days via the tau vein. The control animals were
injected with only the buffer (500 ). 7 animals were taken
for each experiment. Additional controls (2 animals) re-
ceived a solution of sodium ascorbate (33 mg/500 buffer)
or a solution of K2SO4 (Merck, 10 mg/500 buffer). A
single dose of 22.8 [4-14C]cholesterol (159 g) was
administered via the same route in an emulsified form
(300 ) 5 h after the last injection of ascorbic acid sulfate,
sodium ascorbate or K2SO4. This emulsion was prepared as
follows: the benzene was evaporated from the cholesterol
solution and the residue was emulsified in isotonic NaQ after
addition of a small volume of emulgator Atlas O1290 and
propylene glycol. The animals were kept for 72 h.in meta-
bolic cages for the collection of faeces and urine, they had
free access to the diet. After decapitation, the abdomen was
opened and the liver, spleen, kidneys and adrenal glands were
removed and processed for counting of radioactivity
Counting of the radioactive material: The faeces were homo-
genized with a 4-fold amount of water (Polytron, Kinematica,
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Lucerne, Switzerland) and incubated for 10 min at 60° C. The
radioactive material was extracted from the homogenate at
room temperature several times with chloroform/methanol,
10 ml + 10 ml (15-fold volume). After centrifugation, the super-
natants were brought to a constant volume (250 ml). Aliquot s
were counted for radioactivity and were used for Chromato-
graphie identification of the labelled material. The urine was
directly counted for radioactivity (100 μΐ). Solubilization of the
tissues (approx. 50 mg) was achieved with Soluene-100 solubilizer
(Packard) as described in detail elsewhere (12). The radioactivity
was determined using a Nuclear Chicago Unilux II liquid scintil-
lation spectrometer equipped with an Olivetti Programma 101
computerized for direct calculation of disintegrations per min
(dpm). The external standard method for quenche correction
was employed. A mixture of ethanol and scintillator solution
(8 g Butyl-PBD [CIBAJ/1 toluene), 4:15, volumes, was used for
counting.
Chromatography: The extracts from the faeces were chroma-
tographed on thin-layer plates (silica gel Ρ254, Merck). Solvent
systems were as follows: (I) benzene/ethanol/methylethyl-
ketone/water, 30 ml + 30 ml + 30 ml + 10 ml· (13) and (II) ethyl-
acetate/pyridine/acetic acid/water, 62 ml + 21 ml + 6 ml + 1 ml
(14). As standards, cholesterol, cholesterol sulfate and sodium
taurocholate were used. For the quantitative determination of
the composititon of the radioactive material in the faeces,
system II was employed. The 3 labelled fractions were eluted
with chloroform/methanol (10 ml + 50 ml, unpolar zone, chole-
sterol and triglycerides) or with chloroform/methanol (20 ml
+ 10 ml, cholesterol sulfate-containing zone) or with chloroform
(polar zone, sodium taurocholate). The solvents were evaporated
and the amounts of radioactivity were determined in the residues.
Student's t-test was used for statistical evaluation of the data (15).
Results
In Table 1, the values for the total faecal as well as
urinary excretion of 14C-radioactivity are given. A
significant reduction in the faecal excretion of
radioactive material was seen in the first 72 h after the
administration of [4-14C]cholesterol to rats which had
been treated for a period of 5 days with daily injection
of 10 mg or 20 mg ascorbic acid 2-sulfate (27.2% or
28.3% of the labelled dose); the controls received an
injection of buffer only (33.9%) (p < 0.02 and
p < 0.01, respectively), or a solution containing 10 mg
K2SO4 (32.6%). However, sodium ascorbate (33 mg)
had a similar effect to ascorbic acid 2-sulfate, with
regard to the excretion of radioactivity in the faeces
(25.8% of the administered dose). The urinary excretion
of 14C-radioactivity was found to be enhanced
Tab. 2. Percentage composition of the radioactive material
excreted in the faeces after i. v. injection of 22.8 μΟί
[4-l4C]cholesterol into female rats. Treatment prior to
application of cholesterol and number of animals as in
Table 1. The radioactivity was extracted from the faeces
with chloroform/methanol and the extracts were chroma-
tographed on silica gel-coated plates.
Administered
compound
Na+-ascorbate
K2S04
Buffer
Ascorbic acid
2-sulfate
Per cent of excreted radioactivity
mg/day
33
10
10
20
Cholesterol
90.0
93.8
89.9
89.7
90.1
Cholesterol
sulfate
6.1
3.9
6.2
6.3
6.4
Polar
fraction
3.9
2.3
3.9
4.0
3.5
following the injection of 10 mg or 20 mg ascorbic
acid 2-sulfate (2.2% or 2.5% of the dose; treatment with
buffer, 1.6%). The application of sodium ascorbate
(33 mg), or K2SO4 (10 mg) caused an even higher ex-
cretion (3.7% and 3.9%, respectively).
Table 2 summarizes the quantitative composition of the
labelled material in the faeces. Cholesterol and tri-
glycerides (unpolar zone) accounted for nine-tenths of
the radioactivity, whereas only approx. 6% were found
as cholesterol sulfate. The polar fraction contained
3—4% of the label. No stimulatory effect on the ex-
cretion of either cholesterol or cholesterol sulfate could
be observed by ascorbic acid 2-sulfate as compared with
the controls (buffer, sodium ascorbate or K2SO4).
The total radioactivity remaining in the liver, spleen,
kidneys and adrenals 72 h after the single injection of
[4-14C]cholesterol is given in Table 3. The accumulation
of label was higher in the organs of rats injected with
ascorbic acid 2-sulfate. No significant difference existed
either in the liver, spleen, or in the kidneys of rats in the
ascorbic acid 2-sulfate treated group. However, a signi-
ficant increase in the accumulation of radioactivity was
found in the adrenal glands after treating rats with 20 mg
ascorbic acid 2-sulfate (p < 0.02), but the total radio-
activity did not reach the amounts observed after dosage
of either sodium ascorbate or K2 SO4. The weights of the
organs per 100 g of body weight were not influenced
by the treatment with ascorbic acid 2-sulfate.
Tab. 1. Total faecal and urinary excretion of 14C-radioactivity (MCi, rounded figures, SD given) during the first 72 h after i. v.
injection of 22.8 MCi [4-14C]cholesterol (159 Mg) to female rats which had been treated for 5 days with a daily injection of
ascorbic acid 2-sulfate dipotassium salt (10 or 20 mg, n = 7) in 0.15 mol/1 sodium phosphate buffer (pH 7.4) or with buffer.
For additional controls, 2 animals were injected either with 33 mg sodium ascorbate in buffer or with 10 mg K2SO4 in
buffer'. The faeces were extracted as described in the experimental part; the urine (100 μΐ) was directly counted for radio-
activity.
Compound
(mg/day)
Na -ascorbate
33
K2S04
10
Buffer Ascorbic acid 2-sulfate
10 20
Total radioactivity (MCi)
Faeces
Urine
5.89
0.87
7.44
0.89
7.73 ± 0.56***
0.37 ± 0.07*
6.21 ± 1.01**
0.50 ± 0.13
6.45 ± 0.73***
0.56 ± 0.19*
p<0.05; ** p<0.02; %p<0.01.
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Tab. 3. Total radioactivity (μα/100 g body weight; rounded figures, SD given) in various organs 72 h after i. v. appication of
22.8 MCi [4-14CJcholesterol (159 Mg) to female rats. Treatment prior to administration of cholesterol and number of animals
as in Table 1. Solubilization of the organs removed after decapitation was achieved by means of Soluene-luU.
Compound
(mg/day)
Na -ascorbate
33
K2S04
10
Buffer Ascorbic acid 2-sulfate
10 20
* p < 0.02
Total radioactivity (μΟ/ΙΟΟ g body weight)
Liver
Spleen
Kidneys
Adrenals
0.620
0.068
0.095
0.054
0.045
0.068
0.081
0.045
0.401 ± 0.054
0.050 ± 0.014
0.054 ± 0.014
0.012 ± 0.004*
0.482 ± 0.099
0.054 ± 0.009
0.068 ± 0.005
0.021 ± 0,001
0.477 ± 0.095
0.068 ± 0.018
0.068 ± 0.014
0.024 ± 0.009*
Discussion
The effect of intravenously administered ascorbic acid
2-sulfate, given over a period of 5 days, on the excretion
of a single exogenous dose of [14C]cholesterol was
studied in normal female rats. No stimulatory effect of
this ascorbic acid derivative on the excretion of either
free cholesterol or cholesterol sulfate could be ob-
served. On the contrary, treatment with either sodium
ascorbate (33 mg) or ascorbic acid 2-sulfate (10 mg or
20 mg) caused a significant reduction of the total
radioactivity excreted in the faeces (Table 1) in com-
parison with the results obtained after treatment with
buffer or with K2SO4 (10 mg). However, the compo-
sition of the excreted radioactive material was unaf-
fected (approx. 90% cholesterol and 6% cholesterol sul-
fate) (Table 2). The fact that the excretion of labelled
material can be reduced by treatment with sodium
ascorbate is surprising, since the rat is able to produce
ascorbic acid biosynthetically (16). Since ascorbic acid
sulfate treatment evoked a similar effect, the question
arises whether sodium ascorbate can be converted enzy-
matically into ascorbic acid 2-sulfate which then could
be considered as the active compound. Several reports
have appeared indicating an in vivo sulfatation of as-
corbic acid into ascorbic acid 2-sulfate. After the oral
administration of labelled ascorbic acid, ascorbic acid
sulfate was shown to be excreted in the bile (9, 17).
Following the subcutaneous injection of [14C]ascorbic
acid and 35SO|" into rats, [1-14C] ascorbic acid 2-[35S]
sulfate was identified in the liver as well as in other
tissues (10). Ascorbic acid 2-[35S]sulfate was also found
in the rat liver after the intravenous injection of ^SO^"1).
Since ascorbic acid 2-sulfate has been suggested to be
part of the ascorbic acid body pool as a long-term storage
form (8), one might even assume that ascorbic acid
2-sulfate can only evoke this decrease in faecal ex-
1) Hornig, D. (1973) in preparation.
2) Hamilton, J. (1973) in preparation.
cretion after administration of cholesterol as long as
this derivative of ascorbic acid is not integrated in the
ascorbic acid body pool. Our results are in accordance
with the observation that the sulfate moiety of ascorbic
acid 2-sulfate can be transferred in vivo onto cholesterol
to form cholesterol sulfate (3,4). However, the en-
hancement of the faecal excretion of cholesterol sulfate
by ascorbic acid 2-sulfate could not be confirmed
(Table 2). This was postulated from observations follow-
ing the intracardial injection of a single dose of ascorbic
acid 2-[35S]sulfate into rats. This would mean that the
effect of ascorbic acid 2-sulfate on the endogenous
cholesterol was investigated, whereas in our study the
effect of ascorbic acid 2-sulfate was studied on exo-
genously administered cholesterol. However, in studies
with rats in which the cholesterol pool was gradually
labelled by the intravenous application of [14C]meva-
lonate prior to intraperitoneal treatment with ascorbic
acid 2-sulfate, there was still no stimulatory effect
on the cholesterol metabolism with regard to an en-
hanced excretion of 14C-labelled material in the faeces2).
From our studies it is to be concluded that the hypo- *
cholesterolemic effect of ascorbic acid is not attribut-
able to ascorbic acid 2-sulfate.
In the adrenal glands the amount of 14C-radioactivity
was found to be about twice as much in sodium as-
corbate-treated rats as compared with rats pretreated
with ascorbic acid 2-sulfate. On the other hand, the ad-
ministration of ascorbic acid enhanced the concentration
of labelled material derived from [14C]cholesterol in
the adrenals significantly (Table 3). This observation
might possibly be related to an increased hydroxylatiqn
of cholesterol at position C-7 by ascorbic acid 2-sulfate.
In guinea pig liver homogenates cholesterol is mainly
converted to 7a-hydroxycholest-4-en-3-one (18).
Recently, a control function was suggested for ascorbic
acid in the transformation of cholesterol to bile acids
(19). Thus, it would be of interest to study the possible
effect of ascorbic acid 2-sulfate in this transformation
reaction.
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